News Conference News ACC 2025 By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE Michael O'Riordan March 31, 2025
News Conference News ACC 2021 Low 1-Year Stroke Risk After Commercial Watchman Use Todd Neale May 15, 2021
News Conference News ACC 2020 LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout Todd Neale April 06, 2020
News Conference News ACC 2020 New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals Michael O'Riordan April 06, 2020
News Conference News ACC 2020 Hospital MV Surgical Volume Not Tied to TMVr Outcomes Todd Neale March 19, 2020
News Conference News ACC 2017 MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns L.A. McKeown March 27, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2016 Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes Michael O'Riordan April 07, 2016
News Conference News ACC 2016 TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough? Shelley Wood April 03, 2016
News Conference News ACC 2012 ASCERT: Long-term Survival Advantage with CABG in Multivessel Disease Yael L. Maxwell March 27, 2012